How has the lewy body dementia market evolved, and where is it heading next?
The lewy body dementia market size has grown strongly in recent years. It will grow from $1.12 billion in 2024 to $1.21 billion in 2025 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to aging population growth, increasing awareness of neurodegenerative diseases, rise in healthcare expenditures, improved diagnostic criteria, and regulatory approvals for dementia drugs.
The lewy body dementia market size is expected to see strong growth in the next few years. It will grow to $1.60 billion in 2029 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to increasing prevalence of dementia, growing investment in research and development, rising demand for early diagnosis, expanding telemedicine adoption, and focus on personalized medicine. Major trends in the forecast period include development of targeted therapies, expansion of clinical trials, advances in diagnostic techniques, technological advancements, and emphasis on novel therapeutics.
Get Your Free Sample of The Global Lewy Body Dementia Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21213&type=smp
What are the key drivers behind the rapid expansion of the lewy body dementia market?
The rise in the prevalence of brain-related disorders is expected to propel the growth of the lewy body dementia market going forward. Brain-related disorders refer to a range of conditions affecting the brain’s structure and function, leading to cognitive decline, memory loss, and behavioral changes. The prevalence of brain-related disorders is increasing due to factors such as aging, genetic predisposition, and environmental influences. The increasing prevalence of brain-related disorders boosts the demand for better treatments and early detection for lewy body dementia, which in turn drives research, funding, and innovation, leading to faster advancements in diagnosis and therapy for LBD. For instance, in October 2023, according to the World Federation of Neurology, the UK-based association of national neurological societies, more than 40% of the global population is affected by neurological conditions, with this burden expected to almost double by 2050. Therefore, the rise in the prevalence of brain-related disorders will drive the growth of the lewy body dementia market.
What is the segmentation for the lewy body dementia market?
The lewy body dementia market covered in this report is segmented –
1) By Diagnosis: Clinical Diagnosis, Biomarker-Based Diagnosis
2) By Medication: Cholinesterase Inhibitors, Antipsychotics, Antidepressants, Other Medications
3) By End-User: Hospitals, Specialty Clinics, Long-Term Care Facilities, Other End-Users
Subsegments:
1) By Clinical Diagnosis: Neuropsychological Testing, Neurological Examination, Medical History Review, Cognitive Function Assessment
2) By Biomarker-Based Diagnosis: Cerebrospinal Fluid (CSF) Biomarkers, Imaging Biomarkers (PET, MRI), Genetic Biomarkers, Blood-Based Biomarkers
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/lewy-body-dementia-global-market-report
Who are the most influential companies in the lewy body dementia market?
Major companies operating in the lewy body dementia market are Eli Lilly and Company, Mayo Foundation for Medical Education and Research, Eisai Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Georgetown University Medical Center, Alzheimer’s Society, BioArctic AB, Annovis Bio Inc., Sun Pharma Advanced Research Company Limited, Voyager Therapeutics Inc., Cognition Therapeutics, Athira Pharma, Allergan plc, Inhibikase Therapeutics, CuraSen Therapeutics Inc., CervoMed Inc., AC Immune SA, ProMIS Neurosciences Inc., Aptinyx Inc., EIP Pharma Inc.
What are the most influential trends expected to drive the lewy body dementia market forward?
Major companies operating in the lewy body dementia market are focusing on research investment to develop more effective neurodegenerative treatments. Research investment involves dedicating financial resources, time, and effort to scientific and technological studies aimed at uncovering new insights, developing innovative solutions, or enhancing current practices. It supports the exploration of diseases and the creation of new medications, all with the ultimate goal of improving patient outcomes. For instance, in March 2023, the National Institute on Aging, a US-based government agency, awarded $21 million to support drug development research for Lewy Body Dementia (LBD). Researchers at the University of Miami Miller School of Medicine are initiating a Phase 2b study of neflamapimod following encouraging early results.
What are the major regional insights for the lewy body dementia market, and which region holds the top position?
North America was the largest region in the lewy body dementia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lewy body dementia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Lewy Body Dementia Market Report 2025 Offer?
The lewy body dementia market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Lewy body dementia (LBD) is a neurodegenerative condition caused by abnormal protein deposits in the brain, impacting cognition, movement, and behavior. This results in a gradual decline in both mental and physical abilities, with symptoms including memory loss, hallucinations, tremors, and motor difficulties. Effective management is essential to address the cognitive and physical challenges associated with the disorder.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21213
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
